MarketPeel
Insider Trading Intelligence
Pricing
…
WF

W. Michael Flanagan

RNA
CSTO · ATRIUM THERAPEUTICS, INC. · CIK 0001841990
FILING MIX · LIFETIME39%/61%
BUYS
22
SELLS
34
TOTAL VALUE
$19.98M
COMPANIES
2
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
20,000
AVG SELL PX
$41.39
TRADE KIND
SHOWING 56 / 56
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
No backtest data available for W. Michael Flanagan. Backtests are computed for purchase (P) and sale (S) transactions with resolvable price history.
Holdings over time
RNA · 20,000 shares · as of Feb 27, 2026
037,50075,000112,500150,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 22 buys / 34 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
50,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Feb 27, 2026Mar 2, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
66,500——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
150,365——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
88,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
96,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
72,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
Chief Scientific Officer
25,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,558$72.45$185.3K85,093Jan 21, 2026Jan 23, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,976$72.45$288.1K87,651Jan 21, 2026Jan 23, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,373$72.23$171.4K91,627Jan 7, 2026Jan 9, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,500——107,695Dec 17, 2025Dec 19, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Scientific Officer
13,695$71.87$984.3K94,000Dec 17, 2025Dec 19, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Scientific Officer
20,000——76,500Sep 11, 2025Sep 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$38.94$778.7K80,195Sep 11, 2025Sep 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
20,000$14.22$284.4K100,195Sep 11, 2025Sep 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$32.88$657.7K80,195Jun 11, 2025Mar 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
20,000$14.22$284.4K100,195Jun 11, 2025Mar 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Scientific Officer
20,000——96,500Jun 11, 2025Mar 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,780$31.06$365.9K80,195Mar 20, 2025Mar 21, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,000$30.13$602.6K91,975Mar 11, 2025Mar 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
Chief Scientific Officer
20,000$14.22$284.4K111,975Mar 11, 2025Mar 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
Chief Scientific Officer
20,000——116,500Mar 11, 2025Mar 12, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,812$28.59$51.8K91,975Jan 21, 2025Jan 23, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,860$28.60$110.4K93,787Jan 21, 2025Jan 23, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——97,647Jan 6, 2025Jan 8, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Jan 6, 2025Jan 8, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,742$32.66$416.2K72,647Dec 18, 2024Dec 19, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
24,000$35.77$858.4K85,389Dec 11, 2024Dec 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
CSTO
24,000——86,000Dec 11, 2024Dec 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
CSTO
24,000$22.47$539.3K109,389Dec 11, 2024Dec 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
CSTO
62,500——25,000Oct 1, 2024Oct 3, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
62,500$47.62$2.98M85,389Oct 1, 2024Oct 3, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
CSTO
62,500$26.75$1.67M147,889Oct 1, 2024Oct 3, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,153$44.00$578.7K72,718Sep 23, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,847$43.89$520.0K85,389Sep 23, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——85,871Sep 19, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——97,718Sep 19, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,894$40.40$601.7K60,871Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
CSTO
34,000$22.47$764.0K109,765Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
CSTO
62,500$26.75$1.67M138,265Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
62,500$40.40$2.53M75,765Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
34,000$40.40$1.37M75,765Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
CSTO
62,500——87,500Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
CSTO
34,000——110,000Sep 11, 2024Sep 13, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,106$39.13$395.4K50,765Jun 18, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——75,765Jun 17, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——60,871Jun 17, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,129$10.13$41.8K35,871Jan 22, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,290Jan 20, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
88,000——88,000Jan 20, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,000——72,000Sep 11, 2023Sep 12, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,000——40,290Jan 20, 2023Jan 24, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
144,000——144,000Jan 20, 2023Jan 24, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
136,500——136,500Jan 21, 2022Mar 15, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Jan 21, 2021Jan 25, 2021 ↗View →
Other insiders · RNA
Loading peer insiders…
About this filer
CIK 0001841990
ROLE
CSTO
PRIMARY
RNA
COMPANIES
2
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001841990DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback